Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter randomized phase II clinical trial with neo -adjuvant chemotherapy containing eribulin mesylate for triple negative primary breast cancer patients (Neo-Entrance study)

Next Previous
X
Search
Trial Profile

A multicenter randomized phase II clinical trial with neo -adjuvant chemotherapy containing eribulin mesylate for triple negative primary breast cancer patients (Neo-Entrance study)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eribulin (Primary) ; Capecitabine; Carboplatin; Cyclophosphamide; Doxorubicin; Epirubicin; Fluorouracil; Paclitaxel
  • Indications Early breast cancer; Triple negative breast cancer
  • Focus Therapeutic Use
  • Acronyms Neo-Entrance

    • Most Recent Events

    • 21 Sep 2021 Results assessing clinical significance of immune microenvironment of TNBC in association with HRD, germline BRCA1/2 mutation (gBRCAm) and response to NAC presented at the 46th European Society for Medical Oncology Congress
    • 01 Jul 2021 Results published in the Breast Cancer Research and Treatment.
    • 21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top